ICMJE DISCLOSURE FORM

Date:18 May 2021	
Your Name:_Mieke Van Hemelrijck	Manuscript Title: Expectant
Management in Genitourinary Malignancies (Prostate, Bladder,	Kidney)
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the follo	owing box:

None to be declared.			

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

	18.5.21			
	ne:Dr Netty Kins			
Manuscr	ipt Title:	Expectant Manag	gement in Genitourinary Malignancies (Prostate,	
Bladder	, Kidney)			
Manuscr	ipt number (if known	١٠		
· viailasei	pendinoei (ii kilowii	<i></i>		
related to parties w to transp relations	o the content of your whose interests may be earency and does not hip/activity/interest,	manuscript. "Related" me be affected by the content necessarily indicate a bias it is preferable that you d		
The follo manuscri	•	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
i ne autn	or s relationships/act	livities/interests snould be	e <u>defined broadly</u> . For example, if your manuscript perta	ıns
to the ep medication In item #	idemiology of hypert on, even if that medi 1 below, report all su	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months.	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its	ve
to the ep medication In item #	idemiology of hypert on, even if that medi 1 below, report all su	ension, you should declar cation is not mentioned in pport for the work report is the past 36 months. Name all entities with	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments	ve
to the ep medication In item #	idemiology of hypert on, even if that medi 1 below, report all su	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this	se all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your	ve
to the ep medication In item #	idemiology of hypert on, even if that medi 1 below, report all su	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments	ve
to the ep medication In item #	idemiology of hypert on, even if that medi 1 below, report all su	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
to the ep medication In item # the time	idemiology of hypert on, even if that medic 1 below, report all su frame for disclosure	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
to the ep medication In item # the time	idemiology of hypert on, even if that medical frame for disclosure pport for the present	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
In item # the time All su manu	idemiology of hypert on, even if that medic 1 below, report all su frame for disclosure pport for the present script (e.g., funding,	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
In item # the time All sul manu provis	idemiology of hypert on, even if that medical frame for disclosure pport for the present	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
All su medication	pport for the present script (e.g., funding, sion of study materials, cal writing, article ssing charges, etc.)	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
All su medication	pport for the present script (e.g., funding, sion of study materials, cal writing, article	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
All su medication	pport for the present script (e.g., funding, sion of study materials, cal writing, article ssing charges, etc.)	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution)	ve
All su medication	pport for the present script (e.g., funding, sion of study materials, cal writing, article ssing charges, etc.)	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	ve
All su manu provis medic proce	pport for the present script (e.g., funding, sion of study materials, cal writing, article ssing charges, etc.)	ension, you should declar cation is not mentioned in apport for the work report is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	e all relationships with manufacturers of antihypertension the manuscript. The manuscript without time limit. For all other its specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	ve

any entity (if not indicated

None

_Astellas

in item #1 above).

Royalties or licenses

Consulting fees

3

		1	
		Janssen	
5	Payment or honoraria for	Janssen	
	lectures, presentations,	Koelis	
	speakers bureaus,	Astellas	
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Royal Marsden and	
	in other board, society,	Partners	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ase summarize the above c	anflict of interest in the	following have

Please place an "X" next to the following statement to indicate your agreement:

x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.	;